Replay available

BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call

BioLineRx Ltd. (NASDAQ: BLRX) reported Q2 2026 results on this call. Replay available.

Mon, August 31, 2026 at 8:30 AMendedReplay
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Chuck Pallada

Investor Relations

Phil Serlin

Chief Executive Officer

John Vandermusten

Analyst, DAX

Replay transcript excerpt

Call Services. You are now being placed in the conference. . . . . . . . . . . . . . . . Thank you. . . . . . . . . . © The Ultimate Parody Site! . . . . . . . . . Thank you for watching! . . . Directed by Philip Serlin Thank you. . . . © The Ultimate Parody Site! Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2026 Financial Results Conference Call. All participants are presently in a listen-only mode. Following management's formal presentation, instructions will be given for the question and answer session. For operator assistance during the conference, please press Star Zero. I would now like to turn the call over to Chuck Pallada, Investor Relations. Please go ahead. Thank you, Operator, and welcome, everyone, and thank you for joining us on our quarterly results conference call. Earlier today, we issued a press release, a copy of which is available in the investor relations section of our website. It was also filed as a 6K. I'd like to remind everyone that certain statements we make during the call will be forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 20F and our quarterly reports on Form 6K that are filed with the U.S. Securities and Exchange Commission. At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BiLineRx. Thank you, Chuck, and good morning, everyone. And thank you for joining us on today's call. As has been our practice, I will begin with a few I'd like to begin this morning with an update on GLIX-1, our highly innov...

More from Biolinerx Ltd.